Report
Debbie Wang
EUR 100.00 For Business Accounts Only

Zimmer Biomet Sees Improved Growth in 2Q; No Change to Our FVE

Zimmer Biomet delivered solid second-quarter results that were consistent with our expectations and remains on track to hit our full-year projections; we’re standing pat on our fair value. We were particularly pleased to see the firm meet its own deadline to restore inventory levels, especially in large joint reconstruction which remains the firm’s bread and butter. With supply constraints easing, Zimmer Biomet was better able to meet demand from its existing base of surgeons. Quarterly volume a...
Underlying
ZIMMER BIOMET HOLDINGS INC.

Zimmer Biomet Holdings is engaged in musculoskeletal healthcare. The company's products are: Knees, which includes knee replacement surgeries; Hips, which includes hip replacement surgeries; S.E.T., which includes surgical, sports medicine, biologics, foot and ankle, extremities and trauma products; Spine and Craniomaxillofacial and Thoracic, which designs, manufactures and distributes medical devices and surgical instruments, as well as provides face and skull reconstruction products; Dental, which manufactures and/or distributes dental reconstructive implants, dental prosthetic products and dental regenerative products; and Other, which includes bone cement and office based technology products.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Debbie Wang

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch